Understanding Denali as an investment
I previously explored the over-arching potential of the unique 'transport vehicle' platform perfected by Denali Therapeutics (DNLI) for the shuttling of large-molecule therapeutics across the blood-brain-barrier. Since I posted that analysis, the company has added accomplished biologics manufacturing veteran Dana Anderson, PhD, to their team, bolstering my assertion that the company is gearing up for greatness with the 'TV' platform.
As I have laid out in great detail for Second-Level Investing subscribers, Denali's attractiveness as an investment goes well beyond the TV platform. The company is, among other